HDL in obese non-diabetic patients show major alterations in their function and thus their cardio-protective effects. These alterations could be explained by the quantitative and qualitative anomalies in the phospholipids and sphingolipids in the HDL. These molecules play a major role in HDL function and probably present early modifications in obesity, even before the onset of glycaemia deregulation. The aim of this study is to show the presence of qualitative and quantitative modifications of phospholipids and sphingolipids in HDL from obese patients compared with HDL from non-obese controls.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
89
CHU Dijon Bourgogne
Dijon, France
Difference in the mass percentages of total phospholipids + sphingolipids compared with the total HDL mass
in patients with abdominal obesity without hyperglycaemia compared with healthy controls
Time frame: At inclusion
Difference in the percentage of each family of phospholipids or sphingolipids compared with total phospholipids + sphingolipids
in patients with abdominal obesity but without hyperglycaemia compared with healthy controls
Time frame: At inclusion
Difference in the percentage of each sub-family according to the nature of the fatty acids for phosphatidylcholines on the one hand and sphingomyelins on the other in patients
with abdominal obesity but without hyperglycaemia compared with healthy control
Time frame: At inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.